MedTrace Logo

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

NCT00988364 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-11-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is:

* To identify the common factor for L5 prevalence in patients with Metabolic Syndrome.
* To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome patients.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Simvastatin

Simvastatin 20mg daily for 3 months.

DRUG

Vytorin

Vytorin 20/10mg daily for 3 months.

DRUG

Placebo

Placebo one tablet daily times 3 months.

DRUG

Ezetimibe

Ezetimibe 10mg daily for 3 months.

Sponsors & Collaborators

Principal Investigators

  • Chu-Huang Chen, M.D., Ph.D. · Baylor College of Medicine

  • Christie Ballantyne, M.D. · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988364 on ClinicalTrials.gov